Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Enveric Biosciences Advances Drug Development For Mental Health Indications And Intellectual Property Portfolio

Enveric Biosciences Advances Drug Development For Mental Health Indications And Intellectual Property Portfolio

— Advancing to IND-enabling studies with multiple drug candidates — — Enveric’s Growing Patent Portfolio Validated —

byBenzinga Newsdesk

July 13, 2022

1 minute read

— Advancing to IND-enabling studies with multiple drug candidates —

— Enveric’s Growing Patent Portfolio Validated —

First Watch Restaurant Group Files For Offering Of Up To 4.5M Shares Of Common Stock By Selling Stockholders – SEC Filing

By Benzinga Newsdesk

September 12, 4:21 PM

- Reuters Citing SEC Filing

FWRG

Eldorado Gold Posts Q3 Production Above Q2 & Q1 Levels, On Track To Achieve FY23 Target

By Lekha Gupta

October 2, 12:22 PM

Eldorado Gold Corporation (NYSE: EGO) disclosed preliminary

EGO

CSX Gets Price Target Hikes By Analysts After Strong Q1 Results

By Lisa Levin

April 21, 8:25 AM

CSX Corp (NASDAQ: CSX) reported strong first-quarter results.

CSX

Exagen Inc. Announces Select Preliminary Full-Year 2023 Results; Cash Balance Of $36.5M As Of December 31, 2023; Reaffirms FY23 Revenue Guidance Of At Least $50M Vs $50.43M Est.

By Benzinga Newsdesk

January 7, 4:13 PM

Exagen Inc. (NASDAQ:XGN), a leading provider of autoimmune testing solutions, today announces select preliminary unaudited financial results for the full year ended December 31, 2023, and reaffirms its full-year

XGN

Enveric Biosciences Advances Drug Development For Mental Health Indications And Intellectual Property Portfolio

Related Posts

First Watch Restaurant Group Files For Offering Of Up To 4.5M Shares Of Common Stock By Selling Stockholders – SEC Filing

Eldorado Gold Posts Q3 Production Above Q2 & Q1 Levels, On Track To Achieve FY23 Target

CSX Gets Price Target Hikes By Analysts After Strong Q1 Results

Exagen Inc. Announces Select Preliminary Full-Year 2023 Results; Cash Balance Of $36.5M As Of December 31, 2023; Reaffirms FY23 Revenue Guidance Of At Least $50M Vs $50.43M Est.